文献速递免疫规划卫生政策与健康促进

2016-2023年美国临床实践中的水痘-带状疱疹病毒检测

Varicella-Zoster Virus Testing in Clinical Practice in the U.S., 2016-2023.
PubMed 文献 · Am J Prev Med · 2025-03-27

IgG检测占比最高(43%-92%),血清学检测率50-60/万人,PCR检测率约1/万人。血清学检测率约为PCR的50-60倍,IgM检测最高占11%尽管不被推荐用于筛查或诊断。

要点

  • IgG检测占水痘-带状疱疹病毒检测的43%-92%,主要为女性和20-39岁人群。
  • 血清学检测率50-60/万人,PCR检测率约1/万人,前者约为后者的50-60倍。
  • IgM检测最高占11%,尽管不被推荐用于筛查或诊断目的。

核心结论

  • 水痘-带状疱疹病毒血清学检测率比PCR高50-60倍。
  • 血清学检测在女性和年轻成人中更常见,可能由于筛查。
  • 大多数检测似乎与临床管理相关,但发现了不适当的IgM检测。

研究设计与样本

  • 采用描述性分析检查检测频率、患者特征和按检测类型的率。
  • 与检测类型相关的前20个诊断代码用作检测原因的代理。

主要发现

  • 各数据源中IgG检测占比最高(43%-92%),大多数为女性(79%-82%)和20-39岁人群(62%-70%)。
  • 血清学检测率为50-60/万人,PCR检测率约1/万人。
  • 与IgG相关的诊断代码主要归类为常规护理,与病毒学检测相关的归类为急性疾病。
  • IgM检测最高占11%,尽管不被推荐用于筛查或诊断目的。

关键数值与推荐

  • 评估免疫时推荐水痘-带状疱疹病毒特异性免疫球蛋白G(IgG)。
  • 诊断水痘或带状疱疹时推荐实时聚合酶链反应(PCR)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Varicella-zoster virus testing is increasingly needed for assessing immunity and diagnosis in the varicella vaccination era. Varicella-zoster virus-specific immunoglobulin G (IgG) is recommended when assessing immunity; real-time polymerase chain reaction (PCR) is recommended for varicella or herpes zoster diagnosis. The study objective was to describe varicella-zoster virus serologic and virologic testing in U.S. clinical practice. METHODS: Patients with serologic (IgG, immunoglobulin M [IgM]) or virologic (PCR, culture) varicella-zoster virus testing were identified in five administrative data sources (∼11-100 million enrollees; 2016-2023). Descriptive analyses were used to examine varicella-zoster virus testing frequency, patient characteristics, and rates by test type. The top 20 diagnostic codes associated with varicella-zoster test type were used as a proxy for reason for testing. RESULTS: Across data sources, the highest proportion of varicella-zoster virus testing was for IgG (43%-92%); most was in females (79%-82%) and those aged 20-39 years (62%-70%). Rates of serologic testing were 50-60/10,000 persons. Frequency of varicella-zoster virologic testing was considerably lower; PCR testing rates were ∼1/10,000 persons. Diagnostic codes associated with IgG or virologic testing were primarily categorized as routine care or acute illness, respectively. IgM testing was up to 11% of tests, despite not being recommended for screening or diagnostic purposes. CONCLUSIONS: Varicella-zoster virus serologic testing rates were 50-60 times higher than PCR. Serologic testing was more common among females and young adults, likely due to screening. Most varicella-zoster virus testing appeared relevant to clinical management; however, inappropriate IgM testing was identified. Appropriate testing is important to guide clinical and public health management for varicella and herpes zoster.

来源:Am J Prev Med,查看原文。版权归原作者所有。

引用

  1. Raparti L, Leung J, Anderson TC, et al. Varicella-Zoster Virus Testing in Clinical Practice in the U.S., 2016-2023. Am J Prev Med. 2025. PMID: 40157464. doi:10.1016/j.amepre.2025.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。